Peter van Santbrink
Research analist
- Naam
- Ing. P.J. van Santbrink
- Telefoon
- +31 71 527 6076
- santbrin@lacdr.leidenuniv.nl
Research analist
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Biopharmaceutics
- Depuydt M.A.C., Vlaswinkel F.D., Hemme E., Delfos L., Bernabe Kleijn M.N.A., Santbrink P.J. van, Foks A.C., Slütter B., Kuiper J. & Bot I. (2022), Blockade of the BLT1-LTB4 axis does not affect mast cell migration towards advanced atherosclerotic lesions in LDLr-/- mice, Scientific Reports 12(1): 18362.
- Amersfoort J., Schaftenaar F.H., Douna H., Santbrink P.J. van, Puijvelde G.H.M. van, Slütter B., Foks A.C., Harms A., Moreno-Gordaliza E., Wang Y., Hankemeier T., Bot I., Chi H. & Kuiper J. (2021), Diet-induced dyslipidemia induces metabolic and migratory adaptations in regulatory T cells, Cardiovascular Research 117(5): 1309-1324.
- Nahon J.E., Hoekstra M., Havik S.R., Santbrink P.J. van, Dallinga-Thie G.M., Kuivenhoven J.A., Geerling J.J. & Eck M. van (2018), Corrigendum to "Proteoglycan 4 regulates macrophage function without altering atherosclerotic lesion formation in a murine bone marrow-specific deletion model", Atherosclerosis 279: 132-132.
- Amersfoort J., Douna H., Schaftenaar F.H., Foks A.C., Kröner M.J., Santbrink P.J. van, Puijvelde G.H.M. van, Bot I. & Kuiper J. (2018), Defective Autophagy in T Cells Impairs the Development of Diet-Induced Hepatic Steatosis and Atherosclerosis, Frontiers in Immunology 9: 2937.
- Amersfoort J., Schaftenaar F.H., Douna H., Santbrink P.J. van, Kröner M.J., Puijvelde G.H.M. van, Quax P.H.A., Kuiper J. & Bot I. (2018), Lipocalin-2 contributes to experimental atherosclerosis in a stage-dependent manner, Atherosclerosis 275: 214-224.
- Nahon J.E., Hoekstra M., Havik S.R., Santbrink P.J. van., Dallinga-Thie G.M., Kuivenhoven J.A., Geerling J.J. & Eck M. van (2018), Proteoglycan 4 regulates macrophage function without altering atherosclerotic lesion formation in a murine bone marrow-specific deletion model, Atherosclerosis 274: 120-127.
- Heijden T. van der, Kritikou E., Venema W., Duijn J. van, Santbrink P.J. van, Slütter B., Foks A.C., Bot I. & Kuiper J. (2017), NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report, Arteriosclerosis, Thrombosis, and Vascular Biology 37(8): 1457-1461.
- Bot I., Ortiz Zacarias N.V., Witte W.E. de, Vries H. de, Santbrink P.J. van, Velden D. van der, Kroener M.J., Berg D.J. van den, Stamos D., Lange E.C.M. de, Kuiper J., IJzerman A.P. & Heitman L.H. (2017), A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy, Scientific Reports 2017(7): 52.
- Kritikou E., Puijvelde G.H.M. van, Heijden T. van der, Santbrink P.J. van, Swart M., Schaftenaar F.H., Kroner M.J., Kuiper J. & Bot I. (2016), Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice, Scientific Reports 6: 37585.
- Foks A.C., Puijvelde G.H.M. van, Wolbert J., Kröner M.J., Frodermann V., Heijden T. van der, Santbrink P.J. van, Boon L., Bot I. & Kuiper J. (2016), CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice, Cardiovascular Research 111(3): 252-261.
- Frodermann V., Duijn J. van, Puijvelde G.H.M. van, Santbrink P.J. van, Lagraauw H.M., Vries M.R. de, Quax P.H.A., Bot I., Foks A.C., Jager S.C. de & Kuiper J. (2016), Heat-killed Staphylococcus aureus reduces atherosclerosis by inducing anti-inflammatory macrophages, Journal of Internal Medicine 279(6): 592-605.
- Frodermann V., Duijn J. van, Pel M. van, Santbrink P.J. van, Bot I., Kuiper J. & Jager S.C. de (2015), Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development, Scientific Reports 5: 15559.
- Frodermann V., Puijvelde G.H. van, Wierts L., Lagraauw H.M., Foks A.C., Santbrink P.J. van, Bot I., Kuiper J. & Jager S.C. de (2015), Oxidized low-density lipoprotein-induced apoptotic dendritic cells as a novel therapy for atherosclerosis, Journal of Immunology 194(5): 2208-2218.
- Lagraauw H.M., Westra M.M., Bot M., Wezel A., Santbrink P.J. van, Pasterkamp G., Biessen E.A.L., Kuiper J. & Bot I. (2014), Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation, Atherosclerosis 235(1): 196-203.
- Bot I., Daissormont I.T., Zernecke A., Puijvelde G.H.M. van, Kramp B., Jager S.C. de, Sluimer J.C., Manca M., Hérias V., Westra M.M., Bot M., Santbrink P.J. van, Berkel T.J.C. van, Su L., Skjelland M., Gullestad L., Kuiper J., Halvorsen B., Aukrust P., Koenen R.R., Weber C. & Biessen E.A. (2014), CXCR4 blockade induces atherosclerosis by affecting neutrophil function, Journal of Molecular and Cellular Cardiology 74: 44-52.
- Foks A.C., Ran I.A., Frodermann V., Bot I., Santbrink P.J. van, Kuiper J. & Puijvelde G.H.M. van (2013), Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development, PLoS ONE 8(12): e83134.
- Foks A.C., Ran I.A., Wasserman L., Frodermann V., Borg M.N. ter, Jager S.C. de, Santbrink P.J. van, Yagita H., Akiba H., Bot I., Kuiper J. & Puijvelde G.H.M. van (2013), T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis, Arteriosclerosis, Thrombosis, and Vascular Biology 33(11): 2558-2565.
- Bot M., Veldhoven P.P. van, Jager S.C.A. de., Johnson J., Nijstad N., Santbrink P.J. van, Westra M.M., Hoeven G. van der, Gijbels M.J., Mueller-Tidow C., Varge G., Tietge U.J.F., Kuiper J., Berkel T.J.C. van, Nofer J.R., Bot I. & Biessen E.A.L. (2013), Hematopoietic Sphingosine 1-Phosphate Lyase Deficiency Decreases Atherosclerotic Lesion Development in LDL-Receptor Deficient Mice, PLoS ONE 8(5): e63360.
- Foks A.C., Bot I., Frodermann V., Jager S.C. de, Borg M. ter, Santbrink P.J. van, Yagita H., Kuiper J. & Puijvelde G.H.M. van (2012), Interference of the CD30-CD30L pathway reduces atherosclerosis development, Arteriosclerosis, Thrombosis, and Vascular Biology 32(12): 2862-2868.
- Bot I., Vries H. de, Korporaal S.J.A., Foks A.C., Bot M., Veldhoven J.P.D., Borg M.N.D. ter, Santbrink P.J. van, Berkel T.J. van.C., Kuiper J. & Ijzerman A.P. (2012), Adenosine A(2B) Receptor Agonism Inhibits Neointimal Lesion Development After Arterial Injury in Apolipoprotein E-Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology 32(9): 2197-2205.
- Foks A.C., Bot I., Frodermann V., Jager S.C.A. de, Borg M. ter, Santbrink P.J. van, Yagita H., Kuiper J. & Puijvelde G.H.M. van (2012), Interference of the CD30-CD30L pathway reduces atherosclerosis development, Immunology 137: 478-478.
- Calpe-Berdiel L., Zhao Y., Graauw M. de, Ye D., Santbrink P.J. van, Mommaas A.M., Foks A., Bot M., Meurs I., Kuiper J., Mack J.T., Eck M. van, Tew K.D. & Berkel T.J.C. van (2012), Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor knockout mice, Atherosclerosis 223(2): 332-341.
- Calpe-Berdiel L., Zhao Y., Graauw M. de, Ye D., Santbrink P.J. van, Mommaas A.M., Foks A.C., Bot M., Meurs I., Kuiper J., Mack J.T., Eck M. van, Tew K.D. & Berkel T.J.C. van (2012), Macrophage ABCA2 deletion modulates intracellular cholesterol deposition, affects macrophage apoptosis, and decreases early atherosclerosis in LDL receptor knockout mice, Atherosclerosis 223(2): 332-341.
- Jager S.C. de, Canté-Barrett K., Bot I., Husberg C., Puijvelde G.H.M. van, Santbrink P.J. van, Yndestad A., Oever J.M. van den, Kuiper J., Berkel T.J.C. van, Lipp M., Zwaginga J.J., Fibbe W.E., Aukrust P. & Biessen E.A. (2009), Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras, Transplantation 88(5): 631-639.
- Rensen P.C.N., Sliedregt L.A.J.M., Santbrink P.J. van, Ferns M., Schifferstein H.N.J., Leeuwen S.H., Souverijn J.H.M., Berkel T.J.C. van & Biessen E.A.L. (2006), Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor, Arteriosclerosis, Thrombosis, and Vascular Biology 26: 169-175.
- Rensen P.C.N., Sliedregt L.A.J.M., Santbrink P.J. van, Ferns M., Schifferstein H.N.J., Leeuwen SH van, Souverijn J.H.M., Berkel T.J.C. van & Biessen E.A.L. (2006), Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor, Arteriosclerosis, Thrombosis, and Vascular Biology 26: 169-175.
- Rensen P.C., Sliedregt L.A.J.M., Santbrink P.J. van, Ferns M., Schifferstein H.N.J., Leeuwen S.H., Souverein J.H., Berkel T.J.C. van & Biessen E.A. (2006), Stimulation of liver-directed cholesterol flux in mice by novel N-acetylgalactosamine-terminated glycolipids with high affinity for the asialoglycoprotein receptor, Arteriosclerosis, Thrombosis, and Vascular Biology : .
- Bot I., Guo J., Eck M. van, Santbrink P.J. van, Groot P.H., Hildebrand RB, Seppen J., Berkel T.J.C. van & Biessen E.A.L. (2005), Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo, Blood 106: 1147-1153.
- Sliedregt L.A.J.M., Rensen P.C.N., Rump E.T., Santbrink P.J. van, Bijsterbosch M.K., Valentijn A.R.P.M., Marel G.A. van der, Boom J.H. van, Berkel T.J.C. van & Biessen E.A.L. (1999), Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor, Journal of Medicinal Chemistry 42: 609-618.
- Rensen P.C.N., Sliedregt L.A.J.M., Santbrink P.J. van, Berkel T.J.C. van & Biessen E.A.L. (1998), Novel glycolipids with high affinity for the hepatic asialoglycoprotein receptor are potent cholesterol-lowering agents, Circulation 98: I-451.
- Rensen P.C.N., Keulen A.C.I. van, Herijgers N., Sliedregt L.A.J.M., Santbrink P.J. van, Berkel T.J.C. van & Biessen E.A.L. (1998), Recombinant chylomicrons as promosing carriers of DNA for non-viral gene therapy. 14th Lecture Course on Biophysics and Molecular Biology: Development of new vectors and transcriptional switches for the gene therapy of human diseases. Cividale del Friuli, Udine, Italy. [lezing].
Geen relevante nevenwerkzaamheden